While precision oncology requires robust biomarkers, current predictors for lung adenocarcinoma (LUAD) often show limited clinical utility. This study investigates the multifaceted roles of ZC3H12D, a ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

A study led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation, in collaboration with the Clínic-IDIBAPS, has shown for the first time, how lung ...

A study led by the Barcelona Institute for Global Health (ISGlobal) in collaboration with the Clínic-IDIBAPS, has shown, for ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...